Background. A number of demographic and comorbid factors have been demonstrated to be associated with the placement of arteriovenous grafts (AVG) and central venous catheters (CVC) as opposed to native arteriovenous fistulas (AVF). However, no data are available regarding these factors in a hemodialysis population where AVF utilization is high.
The provision of adequate vascular access for patients with end-stage renal disease (ESRD) on hemodialysis is one of the most important challenges facing the clinical nephrologist. Although the native arteriovenous fistula (AVF) is regarded as the vascular access of first choice given its superior patency rate [1] [2] [3] and lower mortality risk [4, 5] compared to synthetic arteriovenous grafts (AVG), the establishment of the AVF remains a significant problem especially in the United States [6, 7] . In recognition of this problem, specific vascular access guidelines [2, 3] and clinical performance measures have been proposed [8] .
In order to increase the overall proportion of AVF, it is critical to identify patient characteristics that are associated with higher rates of both AVG and central venous catheter use. This would then enable targeting of particular patients for a more coordinated approach to access placement, which in turn would increase the AVF utilization rate [7] . To this end, a number of recent studies have identified various patient characteristics (for example, age, female gender, and diabetes mellitus) that are associated with a higher risk for AVG use [9] [10] [11] [12] [13] [14] [15] [16] . The majority of such studies (with two exceptions [13, 16] ) have focused solely on cohorts from the United States where AVF use is low (approximately 30%). Whether these particular characteristics remain a significant barrier to successful AVF creation in a cohort with a high AVF utilization rate is unclear. Recent singlecenter data, for example, has shown that both gender [17] and diabetes mellitus [18] are not impediments to successful AVF creation. We were interested in which patient characteristics would be associated with an increased risk of AVG and catheter use in a large multicenter cohort with a high background AVF prevalence. Gaining insights from a high-prevalence AVF population could help determine which factors can be "overcome" and give additional information that would assist nephrologists and vascular surgeons alike in targeting the patients most at risk of AVG (and catheter) use for earlier AVF construction.
The present study used vascular access data from the Australian and New Zealand Dialysis and Transplant Association (ANZDATA) registry, where AVF prevalence among hemodialysis patients is 75% [19] . The aim of this analysis is to describe factors associated with an increased likelihood of receiving hemodialysis via either an AVG or a catheter in Australia. Additionally, we also examined for differences in practice patterns between the different states in Australia (after accounting for differences in patient characteristics), given that geographic location has previously been shown to be a significant factor for variation in the United States [9, 14] .
METHODS

Study population
The ANZDATA registry collects information on all patients with ESRD in Australia and New Zealand. Data are collected at 6-month intervals in March and September of each year. While data on specific patient outcomes for patients receiving ESRD therapy have been collected since 1977, data on vascular access in hemodialysis patients have only been collected since 1999. All adult patients (age Ն18 years on entry to the ESRD program) receiving hemodialysis in Australia on the September 30, 2001 were eligible to be included in this analysis. Patients are entered in to the registry only when the recovery of renal function is deemed unlikely by the treating physician.
We hypothesized that differences may exist in the factors that are associated with use of an AVG or a catheter as opposed to an AVF between incident patients starting dialysis compared to established prevalent patients. Therefore, we performed the main analysis with the two populations stratified into an incident and prevalent cohort.
Incident patients were defined as any patient who had commenced dialysis treatment in the 12 months prior to September 30, 2001 and, in their first data entry in ANZDATA registry, had been receiving dialysis for Ͻ150 days. Clinical experience suggests that the establishment of permanent vascular access in the form of an AVF can take some months in a number of patients. AVF requires at least 6 to 8 weeks to mature and in some patients multiple interventions may be required to establish a well-functioning AVF. The duration of Ͻ150 days on dialysis was chosen after assessing changes in vascular access patterns for patients grouped in to seven periods of 30-day dialysis duration (corresponding to the first 6 months of dialysis and beyond). Significant differences in access patterns were present in each 30day period up until 150 days of dialysis duration [19] . This was especially evident in patients who were first referred to a nephrologist Ͻ3 months prior to commencing dialysis treatment. Beyond this time point, access patterns were no different to the entire cohort and therefore 150 days was chosen as the cut off point to define the incident and prevalent patient cohorts. The prevalent sample was defined as all patients who commenced dialysis treatment Ͼ12 months prior to September 30, 2001 or if they commenced treatment in the 12 months prior to September 30, 2001 , they had been on dialysis Ն150 days on September 30, 2001 . Dialysis duration for all patients was calculated from the date of first dialysis treatment.
Data collection
The vascular access in use at the time of each survey is reported as one of four options: AVF, synthetic AVG, permanent central venous catheter, or temporary central venous catheter. For the purposes of this analysis, the two central venous catheter categories have been combined together so each patient could have one of the three vascular access types entered at each survey period. Importantly, only the access functioning in use at the time of the survey is collected. For example, if a patient was dialyzing via a catheter but also had an AVF in situ that was not mature, the patient's vascular access would be coded as a catheter. The type of vascular access in use at first hemodialysis treatment was not collected.
The temporary and permanent central venous catheter codes were combined because of possible misclassification arising from interpretation of the definitions. Traditionally, permanent catheters could be regarded as cuffed catheters. However, we had concerns over the interpretation of "permanent" and "temporary." "Temporary" could be regarded as either a non-cuffed "temporary" catheter or any catheter in use while the patient awaits AVF construction and/or maturation. We suspected that the vast majority of Australian units would use a cuffed catheter as this temporary access and therefore we could not be confident that the split between cuffed and noncuffed catheters followed the "permanent" and "temporary definitions" (definitions have now been changed so future surveys collect "cuffed" and "noncuffed" catheters).
The ANZDATA registry also collects information about comorbid conditions for each patient at the start of renal replacement therapy. The presence or absence of coronary artery disease, peripheral vascular disease, cerebrovascular disease, and chronic lung disease is collected (as specified by the treating physician) in three categories: no, yes, or suspected. For the purposes of this analysis, the "yes" and "suspected" groups have been combined. Hypertension requiring treatment, the presence or absence of diabetes (type I or II) and cigarette smoking (never, current, or former smoker) is also collected. If the patient began dialysis treatment Ͻ3 months after being first referred to a nephrologist, this is defined as a "late referral." Torres Strait Islanders were combined with Aboriginal patients in this analysis (Indigenous Australians).
Body mass index (BMI) was calculated from the height and weight data and was initially modeled separately both as a continuous and then categorical variable split in four categories: Ͻ20 kg/m 2 , 20 to 24.9 kg/m 2 , 25 to 29.9 kg/m 2 , and Ն30 kg/m 2 . This was done to assess whether both a low and high BMI could be associated with higher risk of AVG and/or catheter use. Dry weight at the time of the survey completion was used for the calculation of the BMI. Duration of dialysis was also modeled as a categorical factor, split into quartiles. All data are collected by the treating renal units on paperbased returns and sent to ANZDATA where it is entered manually into the registry database.
Statistical analysis
All values are presented as median (interquartile range) or total number (percentage). Baseline characteristics between the incident and prevalent groups were compared using the Mann-Whitney U test for continuous variables and the 2 test for categorical variables. Comparison between the different vascular access types within the two cohorts was performed using the Kruskal-Wallis test for the continuous variables and the 2 test for categorical variables.
As the type of vascular access in use at the time of the survey could be any one of the three access types, multinomial (polytomous) logistic regression was used [20] . Multinomial logistic regression is an extension of logistic regression for analysis of a nominal outcome variable with three or more categories [20, 21] . The AVF was used as the comparison group and all analyses were stratified according to the incident/prevalent status except the geographic analysis or where stated (see below). Potential independent factors associated with access type were first assessed separately to give crude estimates and to assess potential confounding factors. All statistically significant factors and any other factors thought to be clinically important, regardless of statistical significance, were then entered into the final model. Models were built for each cohort separately. Additionally, potential interactions (effect modification) between gender and diabetes mellitus (type I and type II separately) and BMI were assessed.
Following the creation of the final model, a second analysis on the whole patient cohort was performed assessing the different access patterns among the different states in Australia, adjusted for differences in patient characteristics. In the analysis of state-specific data, the overall national proportions of the three access types was used as the comparison given that each state does not necessarily represent a single managing network in its own right. We considered a finding to be statistically significant if the two-sided P value was less than 0.05.
All analyses were conducted using Intercooled Stata 7.0 (StataCorp, College Station, TX, USA).
RESULTS
Cohort description
A total of 5516 patients were recorded as having received hemodialysis treatment in Australia during the 12-month study period. We excluded 548 patients, 160 because as they were less than 18 years of age at their first hemodialysis treatment and 388 because they had died during the 12 months prior to September 30, 2001, leaving 4968 patients were eligible for analysis. Table 1 summarizes the demographic and clinical characteristics of the patients divided into the incident and prevalent cohorts, respectively. The majority of patients in both cohorts dialyzed using an AVF. AVF and AVG were more common in the prevalent versus incident cohort, whereas catheters were more prevalent in the incident cohort. Incident patients were older and more likely to have type II diabetes mellitus but had a lower prevalence of coronary artery disease, peripheral vascular disease, cerebrovascular disease, and lung disease. There were no significant differences between the two groups with respect to gender, race, BMI, late referral, hypertension, and smoking status.
Clinical characteristics and AVG use
Results of the univariable and multivariable analysis for AVG versus AVF are presented in Table 2 , grouped into the incident and prevalent cohorts. In the incident cohort, females were three times more likely than males to receive an AVG compared to an AVF. Likewise, both increasing age and type I diabetes mellitus were also significantly associated with an increased likelihood of AVG use (with a greater than fourfold increase in odds for patients with type I diabetes mellitus). In contrast to patients with type I diabetes mellitus, those with type II diabetes mellitus did not have an increased likelihood of AVG use. The odds ratio (OR) for both types of diabetes mellitus was also significantly different from each other (Wald test, P Ͻ 0.02). Coronary artery disease, peripheral vascular disease, cerebrovascular vascular disease, and both current and former smokers were not associated with increased odds of AVG utilization. Obese patients (BMI Ն30 kg/m 2 ) were 79% more likely to receive an AVG versus an AVF compared to nonobese patients, although this was of borderline statistical significance. Indigenous patients were 66% less likely to receive an AVG compared to Caucasians. Late referral was not associated with a significantly elevated likelihood of AVG placement in the incident cohort.
Results for the prevalent cohort revealed differences to the incident cohort. Of the factors that were associated with a significantly increased AVG utilization in the inci- Diabetes proportion overall, not as the cause of ESRD dent cohort, age, female gender, BMI Ն30 kg/m 2 and indigenous racial origin had point estimates that were essentially unchanged. However, type I diabetes mellitus was no longer associated with an increased likelihood of AVG use in this cohort. Patients with peripheral vascular disease were 19% more likely to have recieved an AVG in the prevalent cohort. Additionally patients receiving treatment for 3.5 to 5.9 and Ն6 years were more likely to dialyze with an AVG. Coronary artery disease, type II diabetes mellitus, smoking, late referral, BMI Ͻ20 kg/m 2 , Maori/Pacific Islanders, and other racial subgroups remained nonsignificant in the prevalent cohort.
Clinical characteristics and catheter use
Results for each cohort regarding catheter use versus AVF are presented in Table 3 . Similar to the AVG data, both female gender and type I diabetes mellitus had a significantly increased likelihood of catheter use in the incident cohort. In addition, type II diabetes mellitus patients also had a significantly increased likelihood of catheter use. Not surprisingly, late referral was associated with the highest likelihood of catheter use, reflecting the need for early referral to enable fistula construction and maturation. Racial origin was also an important factor. Despite being twice as likely to be referred late (OR 2.12, 95% CI 1.73 to 2.60, P Ͻ 0.001), incident indigenous patients were less likely to receive hemodialysis via a catheter. Unlike the AVG data, patients with a BMI Ն30 kg/m 2 had a lower likelihood of catheter use that was of borderline statistical significant. Age was not a significant factor for catheter use in this cohort.
In the prevalent cohort, the association of peripheral vascular disease was stronger as was the effect of gender. Current smokers were more likely to receive a catheter, whereas there was no association between type II diabetes mellitus and catheter use, in contrast to the results of the incident cohort. Catheter use was also significantly less likely in patients receiving dialysis for longer than 2 years and late referral was no longer a significant factor. Age, BMI, race, coronary artery disease, and cerebrovascular disease were not associated with an increased likelihood of catheter use. Table 4 shows OR for AVG utilization in females who were either diabetic, or had either a low or high BMI.
Gender, diabetes, and BMI interaction
In the incident cohort, the combination of female gender and diabetes mellitus had a potent effect on the odds of AVG use, especially for type I diabetic patients. The combination of gender and diabetes mellitus made less of an impact in the prevalent cohort with increased rates in type I patients only given that type II diabetes mellitus was not a significant factor for AVG use (aOR for females is the same for females with type II diabetes mellitus). However, we did not find any evidence for a differential effect of diabetes mellitus on AVG use according to gender (effect modification) in either cohort (P values for interaction between gender and diabetes mellitus all Ͼ0.05). Similar to the diabetes mellitus results in the incident cohort, females with a high BMI (Ն30 kg/m 2 ) had a high likelihood of AVG use. This effect persisted and remained significant in the prevalent cohort. Again, there was no evidence for any interaction between gender and BMI in either cohort (P values all Ͼ0.05).
Similar to the AVG data, the combination of female gender and type I diabetes mellitus was a strong marker for catheter use in the incident and, to a lesser extent, in the prevalent cohort. The combination of a high or low BMI with female gender was not associated with an excessive increased risk compared to female gender alone. We found no evidence for any significant interaction between gender and diabetes mellitus and gender Table 5 and Figure 1 present the proportion of AVG and catheters for the whole cohort of patients divided in to the six states and one territory (the Australian Capital Territory data has been combined with New South Wales). Significant variation was seen in the distribution of AVG and catheter use. Using the overall national proportions as the comparison group, New South Wales and the Australian Capital Territory had the highest proportion of patients with AVG at 30%. After adjusting for differences in demographic and comorbid factors, patients in New South Wales and the Australian Capital Territory were four times as likely to receive hemodialysis via an AVG. Correspondingly, patients in Tasmania and South Australia were the least likely to receive an AVG.
National vascular access practice patterns
There was also a wide variation in the proportions of catheters ranging from 4% in South Australia to 20% in Tasmania. After adjusting for confounding factors, the highest likelihood was seen in Western Australia. Overall, South Australia had the lowest combined proportions of AVG (6%) and catheter (4%) use, with both adjusted OR significantly below the national average.
DISCUSSION
This study demonstrates that, despite an overall high prevalence of AVF, there remains a particular subset of patients who have a significantly lower probability of receiving hemodialysis via an AVF. In addition, the previously demonstrated influence of differing practice patterns seen within the United States [9, 14] on AVF utilization is also evident among the different areas in Australia. As we were able to assess the entire cohort of patients receiving hemodialysis during the study period, these results can be considered representative of the trends in vascular access use in Australia. Additionally, we have not limited the analysis to AVG and AVF alone or catheter and AVF by collapsing vascular access types in to a binary variable for analysis with ordinary logistic regression thus enabling full exploitation of the data [21] .
Overall, 61% of incident patients were receiving hemodialysis via an AVF, with 28% using a catheter and 11% an AVG. The proportion of AVF increased by 16% to 77% in the prevalent cohort with a corresponding reduction in catheters to 4%. Although different patients are studied in each cohort, these trends suggest that most centers in Australia are attempting AVF construction in the majority of patients, with a catheter used as a bridge to maturation if necessary. This is also supported by the fact that time on dialysis was not associated with AVG use until it was Ն3.5 years' duration. As we do not have data on the vascular access used at first hemodialysis, the proportion of patients commencing hemodialysis with an AVF is not clear. However, a recent analysis of all patients who had begun hemodialysis less than 30 days prior to their first entry into the ANZDATA registry revealed an AVF rate of only 50% and a catheter rate of 45% [19] . This provides strong indirect evidence that a large number of patients do not have a mature functioning AVF prior to commencing hemodialysis in Australia. In contrast, while the definition of the incident cohorts differed (patients on dialysis Ͻ90 days were excluded), AVF use in the recent ESRD Clinical Performances Measures (CPM) project study was only 29% with the catheter rates similar at 30%. There was no increase in the AVF proportion in the prevalent sample and only a small reduction in catheter use to 22%. The major access of use was the AVG in both cohorts. While the two populations were different with respect to age and the presence of diabetes, this does provide insights into the different approach to vascular access between the two countries. Large variations in the proportion of patients commencing hemodialysis with an AVF have also recently been demonstrated in an analysis of Dialysis Outcomes and Practice Patterns Study (DOPPS) data from the United States, Europe, and Japan [22] . Therefore, the early construction of AVF to allow sufficient time for maturation is an important problem in a number of countries even in those with a high overall AVF prevalence.
Assessment of the differing comorbidity associations in access type across each cohort enables inferences to be drawn regarding overall practice patterns in Australia. Incident type II diabetes mellitus patients had an increased likelihood of catheter use coupled with no increased in AVG use, suggesting that a significant number of type II diabetes mellitus patients require the use of catheters as a bridge to AVF maturation. Whether this represented an increased difficulty in establishing AVF in type II diabetes mellitus or the requirement of a longer maturation time cannot be answered by this analysis. In contrast, in the CPM study [14] , diabetes mellitus patients had a significantly lower risk of catheter use and a higher risk of AVG use (assuming that the majority of patients in that study had type II diabetes). This suggests the opposite clinical scenario where diabetes mellitus patients are preferentially receiving an AVG first instead of an AVF [14] . Diabetes mellitus has been associated with higher rates of AVG use in other studies from the United States [9, [11] [12] [13] [14] and Europe [13] . Others have shown that it is possible to achieve the same proportion of AVF in patients with diabetes mellitus as nondiabetic patients [23, 24] . Of concern was the risk of AVG in incident type I diabetic patients (although numerically they are a relatively small number of patients), especially if the patients were female. As previous studies did not separate type I and II diabetes, it is unclear whether this is reflective of local Australian practice or a more general effect of type I diabetes melli-tus. Clearly, this group requires further attention to increase AVF rates in Australia.
In contrast to type II diabetes mellitus, we found that subjects with a BMI Ն30 kg/m 2 had an increased likelihood of AVG use of similar magnitude in both cohorts, without any increase in the odds of catheter use. Thus unlike the type II diabetic patients, AVG seem to be inserted in preference to attempting AVF in this group. Obesity has also been shown previously to be a significant risk factor for AVG use [10] [11] [12] [13] [14] . Peripheral vascular disease was significantly associated with AVG use in the prevalent cohort but not in the incident cohort. This suggests that AVF were being attempted despite the presence of peripheral vascular disease but in the longterm a significant number of patients required an AVG (or catheter given that it was significant in this group as well). The presence of significant vascular disease may impair arterial inflow, delaying AVF maturation, and reducing AVF longevity. Most [9, 11, 13] but not all [12] studies from the United States have also demonstrated an association between peripheral vascular disease and AVG use. The independent association of cerebrovascular disease with AVG in both the cohorts has not to our knowledge been demonstrated before. Hirth et al [9] failed to demonstrate any association between a history of cerebrovascular disease and AVG use, and further study is needed to clarify whether any true association exists. The data for coronary artery disease are also consistent with three recent studies [9, 10, 12] , failing to show any association with AVG use, with the recent DOPPS study incorporating both patients from the United States and Europe the only exception [13] .
Aboriginal (indigenous) people in Australia have been shown to have a greater burden of comorbid disease at the beginning of renal replacement therapy [25] and are more likely to be referred late to a nephrologist prior to commencing dialysis [26] . Despite these factors, they were less likely to receive an AVG as opposed to an AVF. The establishment of a multidisciplinary team approach to vascular access management in the Northern Territory, which has a large proportion of the indigenous patients [27] , is likely to be a factor contributing to the lower rates of AVG use in this subgroup. Although not completely comparable, black race is associated with AVG in some [10, 11, 14] but not all United States studies [9, 12] . Black patients have also recently been shown to have a significantly lower likelihood of catheter use at first hemodialysis and a higher probability of permanent vascular access placement prior to starting hemodialysis (this study did not differentiate between AVF and AVG) [15] . This finding has been suggested as one possible explanation for the apparent favorable survival advantage of black patients seen in the United States Renal Data System (USRDS) database [15] .
Overall, there are a number of similarities and differ-ences in the patterns between Australia, Europe, and the United States. Increasing age, female gender, and obesity are significant impediments to AVF utilization in Australia, the United States, and Europe [9] [10] [11] [12] [13] [14] 16] . Recent single-center data concerning the effect of gender are conflicting, with one study demonstrating that the gender differences persist even after the use of preoperative vein mapping and frequent interventions to salvage immature AVF [28] , while another did not find any gender differences in AVF prevalence [17] . The lack of association of type II diabetes mellitus to AVG use seen here and by others [18, 23] , suggests that given pre-ESRD care, AVF use can be increased in this patient group. Taken together, these studies suggest that while anatomic and comorbid factors are important, physician practice patterns are also a very important determinant in the type of access placed in different patients. We have demonstrated that, similar to studies in the United States hemodialysis population [9, 14] , significant differences exist in vascular access practice patterns across the different states and territories in Australia. This effect persisted even after accounting for differences in patient demographics. This is important as it demonstrates that differences over geographic location are not just unique to the United States hemodialysis population, especially given the different health care structures between the two countries. Explanations for the differences between the geographic regions in Australia are likely to be multifactorial. Physician and possibly nursing attitudes are probably important (as shown in a recent study of United States DOPPS data [29] ). Differences in access to vascular surgeons and the availability of operating theater time may also be important determinants, especially in the construction of AVF sufficient time before dialysis commencement. Identifying factors in centers (or regions) that are performing well can assist the centers that are not performing as well to increase their overall AVF rates. This has been demonstrated in Australia in the Northern Territory, where AVF patency rates have increased with the introduction of a multidisciplinary team approach to vascular access [27] . It is likely that the ongoing DOPPS studies [30] will shed more light on not only possible explanations for the discrepancies between Australia, Europe, and the United States but also in the differences in practice patterns across geographic location.
Despite being comprehensive in its data capture, there are a number of limitations to this study. First, the data on comorbidity are based on the opinion of the treating physician, and not strictly defined criteria as would be ideal. In addition, there was no information on the severity of disease, and the comorbidity data were collected at the time of commencing dialysis (this has currently changed where comorbidity is updated at each survey). The data here represent only a cross-section in time and so this analysis does not detect potential changes in vascular access over time for individual patients; therefore, differing associations between the two cohorts would need to be confirmed in a prospectively followed group. The data set does not provide information on AVF attempt rates in the incident patients. Thus, the proportion of patients in whom an AVF was attempted, failed, and subsequently received an AVG is unknown. Also, as noted previously, the ANZDATA registry is not currently externally audited and therefore the veracity of the data is not assessed independently [31] .
CONCLUSION
Despite a high overall prevalence of AVF use in Australia, a significant number of patients receive an AVG and catheter despite the known detrimental effects. Both age and gender and late referral and gender were strong predictors of AVG and catheter use, respectively. Despite a moderately high AVF prevalence in the new patients commencing hemodialysis, a significant proportion begin dialysis using a catheter. The encouraging factor is that AVF use increases further in the prevalent cohort. In addition, risks for both AVG and catheter vary significantly across Australia, suggesting a role for physician bias in permanent vascular access placement. The provision of adequate pre-ESRD care for all patients with renal failure is required to further enhance the utilization of AVF in Australia and in particular reduce catheter rates in patients commencing hemodialysis as renal replacement therapy.
